Cite
Repurposing Metformin, Simvastatin and Digoxin as a combination for Targeted therapy of Pancreatic Ductal Adenocarcinoma
MLA
Stephen Markowiak, et al. Repurposing Metformin, Simvastatin and Digoxin as a Combination for Targeted Therapy of Pancreatic Ductal Adenocarcinoma. Aug. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....43ce0bbc70998c0f54428dce7848204e&authtype=sso&custid=ns315887.
APA
Stephen Markowiak, Andrea Kalinoski, Robbi Sanchez, Juehua Yu, Jian-Ting Zhang, John Nemunaitis, Robert Damoiseaux, F. Charles Brunicardi, Jeffrey M. Sutton, Shi-He Liu, Paul W. Erhardt, & Justin F. Creeden. (2020). Repurposing Metformin, Simvastatin and Digoxin as a combination for Targeted therapy of Pancreatic Ductal Adenocarcinoma.
Chicago
Stephen Markowiak, Andrea Kalinoski, Robbi Sanchez, Juehua Yu, Jian-Ting Zhang, John Nemunaitis, Robert Damoiseaux, et al. 2020. “Repurposing Metformin, Simvastatin and Digoxin as a Combination for Targeted Therapy of Pancreatic Ductal Adenocarcinoma,” August. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....43ce0bbc70998c0f54428dce7848204e&authtype=sso&custid=ns315887.